Skip to main content

Tanezumab in Osteoarthritis: Data Presented at OARSI

May 15, 2015 12:45 am

Pooled analyses of the tanezumab (a nerve growth factor inhibitor) phase 3 studies was presented at the 2015 Osteoarthritis Research Society International (OARSI) World Congress. Safety and efficacy data from 2,979 patients with moderate-to-severe hip or knee OA (25% had severe OA) is detailed in this report. Adverse events and withdrawals were equal to comparators but more than placebo. Neuropathic sensations were more common on the biologic (5.8%) compared to placebo (1.7%).

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.